APP Settles Patent Row Over Generic Blood Thinner

Law360, New York (January 24, 2012, 8:20 PM EST) -- APP Pharmaceuticals LLC and The Medicines Co. signed a deal on Monday that suspends APP's work on producing a generic version of MDCO's blood thinner Angiomax until 2019 and drops all pending litigation between the companies.

Under the terms of the settlement announced Monday, APP will license multiple generic products to MDCO and secure a license to produce a generic version of Angiomax, or bivalirudin, starting May 1, 2019. In addition, APP will manufacture and supply Angiomax to the Parsippany, N.J.-based company, MDCO said in a...
To view the full article, register now.